The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

Pharmacogenetics

Volumn 12, Issue 1, 2002, Pages 3-9

  Lötsch, Jörn ^a   Skarke, Carsten ^a   Grösch, Sabine ^a   Darimont, Jutta ^a   Schmidt, Helmut ^a   Geisslinger, Gerd ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Morphine; Morphine 6 glucuronide; Opioid receptors; Pharmacogenetics

Indexed keywords

MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; LIGATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PUPIL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MORPHINE DERIVATIVES; MUTATION; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUPIL; RECEPTORS, OPIOID, MU;

SIGMOIDEA;

EID: 0036152705     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200201000-00002     Document Type: Article

References (33)

1. Analgesic effect of morphine glucuronides
2. Morphine-6-glucuronide concentrations and opioid-related side effects: A survey in cancer patients
3. Action at the mu receptor is sufficient to explain the supraspinal analgesic effect of opiates
4. No heroin or morphine 6beta-glucuronide analgesia in mu-opioid receptor knockout mice
5. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene
6. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia
7. Incomplete cross tolerance and multiple mu opioid peptide receptors
8. Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor
9. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1
10. Opioid receptor and peptide gene polymorphisms: Potential implications for addictions
11. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction
12. The transfer half-life of morphine-6-beta-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers
13. The LightCycler: A microvolume multisample fluorimeter with rapid temperature control
14. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function
15. Pain genes?: Natural variation and transgenic mutants
16. Evidence for allelic association of the dopamine beta-hydroxylase gene (d.b.h.) with susceptibility to typical migraine
17. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura
18. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region
19. Congenital insensitivity to pain with anhidrosis: Novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor
20. Impact of environmental and genetic factors on codeine analgesia
21. Patient-controlled analgesia (PCA) with codeine for post-operative pain relief in 10 extensive metabolisers and one poor metaboliser of dextromethorphan
22. Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects
23. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
24. The mu opiate receptor as a candidate gene for pain: Polymorphisms, variations in expression, nociception, and opiate responses
25. Sequence variability and candidate gene analysis in complex disease: Association of mu opioid receptor gene variation with substance dependence
26. Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action
27. Chronic nausea and morphine-6-glucuronide
28. Explanation for potency of repeated oral doses of morphine?
29. Analgesic action of iv morphine-6-glucuronide in healthy volunteers
30. The analgesic activity of morphine-6-glucuronide
31. Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers
32. Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief
33. Pharmacogenetics and adverse drug reactions